Literature DB >> 32317365

Microbial clues lead to a diagnosis of cystic fibrosis in late adulthood.

Colm Kerr1, David Morrissy2,3, Mary Horgan4, Barry J Plant5,3.   

Abstract

Cystic fibrosis (CF) is the most common life-limiting autosomal recessive genetic disorder among Caucasian populations. The majority of CF cases are diagnosed in childhood; however, increasing numbers of adults are being diagnosed with the condition. We present the case of a 65-year-old Irish woman presenting with a chronic cough and a history of recurrent respiratory tract infections. Staphylococcus aureus, Scedosporium apiospermum and Stenotrophomonas maltophilia were grown from bronchoalveolar lavage raising suspicion for CF. Sweat testing was negative; however, genetic testing revealed the presence of ∆F508 and R117H CF mutations, the latter mutation conferring a milder form of CF. The patient commenced treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator medication ivacaftor to good effect. Novel CFTR potentiators and modulators have significant potential to benefit morbidity and mortality in this group. In this case, the microbiological results were key in pursuing genetic testing and diagnosing CF. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cystic fibrosis; genetics; infectious diseases; respiratory medicine; respiratory system

Mesh:

Substances:

Year:  2020        PMID: 32317365      PMCID: PMC7202750          DOI: 10.1136/bcr-2019-233470

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis.

Authors:  Margarida D Amaral; Karl Kunzelmann
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

2.  Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis.

Authors:  Jerry A Nick; Cathy S Chacon; Sara J Brayshaw; Marion C Jones; Christine M Barboa; Connie G St Clair; Robert L Young; David P Nichols; Jennifer S Janssen; Gwen A Huitt; Michael D Iseman; Charles L Daley; Jennifer L Taylor-Cousar; Frank J Accurso; Milene T Saavedra; Marci K Sontag
Journal:  Am J Respir Crit Care Med       Date:  2010-05-06       Impact factor: 21.405

Review 3.  Manifestations of cystic fibrosis diagnosed in adulthood.

Authors:  Jerry A Nick; David M Rodman
Journal:  Curr Opin Pulm Med       Date:  2005-11       Impact factor: 3.155

4.  Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.

Authors:  Sabine Hadida; Fredrick Van Goor; Jinglan Zhou; Vijayalaksmi Arumugam; Jason McCartney; Anna Hazlewood; Caroline Decker; Paul Negulescu; Peter D J Grootenhuis
Journal:  J Med Chem       Date:  2014-12-02       Impact factor: 7.446

Review 5.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Future trends in cystic fibrosis demography in 34 European countries.

Authors:  Pierre-Régis Burgel; Gil Bellis; Hanne V Olesen; Laura Viviani; Anna Zolin; Francesco Blasi; J Stuart Elborn
Journal:  Eur Respir J       Date:  2015-03-18       Impact factor: 16.671

Review 7.  Cystic fibrosis since 1938.

Authors:  Pamela B Davis
Journal:  Am J Respir Crit Care Med       Date:  2005-08-26       Impact factor: 21.405

8.  Early airway infection, inflammation, and lung function in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood; Claire Wainwright
Journal:  Arch Dis Child       Date:  2002-10       Impact factor: 3.791

Review 9.  Management of comorbidities in older patients with cystic fibrosis.

Authors:  Barry J Plant; Christopher H Goss; William D Plant; Scott C Bell
Journal:  Lancet Respir Med       Date:  2013-03-19       Impact factor: 30.700

10.  Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

Authors:  Samiya Razvi; Lynne Quittell; Ase Sewall; Hebe Quinton; Bruce Marshall; Lisa Saiman
Journal:  Chest       Date:  2009-06-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.